Skip to main content

Table 1 Overview of differentially mutated melanoma cell lines tested.

From: Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations

Cell Line BRAF/NRAS BRAF
Gene Copies
Other Oncogenic Events IC50 for single agent vemurafenib IC50 for single agent metformin
M257 Wild type 3 CDKN2A R80 12.2 μM 16.4 mM
M202 NRASQ61L 2 EGFR amplification, CDKN2A -/- > 20 μM 25.3 mM
M207 NRASQ61L 2 MITF amplification, PTEN -/+ > 20 μM 25.2 mM
M244 NRASQ61L NT NT 19.9 μM 22.7 mM
M296 NRASQ61L NT NT 19.4 μM 9.0 mM
SKMEL173 NRASQ61K NT NT > 20 μM 36.5 mM
WM1366 NRASQ61L NT NT > 20 μM 8.6 mM
SBCL2 NRASQ61L NT NT > 20 μM 2.9 mM
M229 BRAFV600E homozygous 4 MITF amplification, AKT1 amplification
PTEN -/+
0.3 μM 13.0 mM
M233 BRAFV600E heterozygous 3 AKT1 amplification, CCND1 amplification
EGFR amplification, CDKN2A -/-, PTEN -/-
> 20 μM 20.2 mM
M238 BRAFV600E heterozygous 2 CDKN2A -/-, PTEN -/+ 0.1 μM 12.5 mM
M238-AR5 BRAFV600E heterozygous 2 CDKN2A -/-, PTEN -/+, PDGFR1b over-expression > 20 μM 13.1 mM
M249 BRAFV600E heterozygous 3 MITF amplification, AKT2 amplification, PTEN -/- 0.1 μM 9.2 mM
M249-AR4 BRAFV600E heterozygous
NRASQ61K
3 MITF amplification, AKT2 amplification, PTEN -/- > 20 μM 17.9 mM
M255 BRAFV600E heterozygous 2 AKT2 amplification, CCND1 amplification
EGFR amplification, CDKN2A -/-
8.8 μM 17.3 mM
M262 BRAFV600E homozygous 2 AKT1 E17K, AKT1 amplification
EGFR amplification, CDKN2A -/-
0.2 μM 20.5 mM
M263 BRAFV600E heterozygous 2 CDKN2A -/+ 19.9 μM 19.6 mM
M308 BRAFV600E heterozygous 3 MITF amplification
AKT2 amplification, EGFR amplification
CDKN2A-/+
17.3 μM 6.0 mM
SKMEL28 BRAFV600E homozygous 2 EGFR P753S, MITF amplification
CCND1 amplification, CDKN2A -/+,
PTEN -/+
1.5 μM 29.7 mM
  1. Legend: NT: not tested.